Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Business Description

Grifols SA (Grifols) is a specialty pharmaceutical company that develops, manufactures and distributes biological medicines based on plasma derived proteins. It offers in vitro diagnostics products for use in clinical and blood bank laboratories; and nutrition products, infusion solutions and medical devices for use in clinics and hospitals. The protein-based therapies enhance the lives of people suffering with chronic and acute life-threatening, conditions such as chronic inflammatory demyelinating polyneuropathy, immunological deficiencies, A1PI deficiency and related emphysema, traumatic or hemorrhagic shock and severe burns, among others.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

R&D Overview

Grifols’ R&D activities are focused on developing products, researching new applications for existing products, and improvement of manufacturing processes to enhance yields, safety and efficiency. The company focuses on the development of in vitro diagnostic reagents, assays, instrumentation, and software for donor screening. It supports various business areas such as transfusion medicine, clinical diagnostics, and the recombinant protein business. It also focuses on the delivery of products, integrated technology solutions, and services that enhance safety, quality and efficiency in operational pharmacy. The key technologies include NAT technology and gel agglutination technology. In FY2021, it spent EUR299.57 million on R&D, which as a percentage of revenue stood at 6.07%. As of December 31, 2021, it had 3,525 patents, including 354 in North America, 1,707 in Europe and 1,464 worldwide. It had 928 patent applications; and also owned 3,557 trademarks across the world.

Business Segments

Overview

Includes all transactions related to biological products for non-therapeutic use.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Overview

Employs proteins extracted from human plasma to produce therapeutic medicines for the treatment of chronic, rare and life-threatening conditions. Its therapies treat a wide range of medical conditions, including coagulation disorders, pulmonary disorders, immune deficiencies, shock and trauma, liver cirrhosis, and infectious. The segment oversees all activities including plasma collection and manufacturing; plasma testing and analysis; R&D; manufacturing; marketing and worldwide distribution. - Key plasma products include intravenous immunoglobin; albumin; HyperRAB anti-rabies immunoglobulin; Koate-DVI, used to prevent and control bleeding in Factor VIII deficiency; and Xembify used to treat Primary Humoral Immunodeficiency. Continue to develop new formulations and indications of its therapies to meet growing needs of people across the world.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Overview

Provides in vitro diagnostics products, including reagents, analytical instruments, software and related products for use in clinical and blood bank laboratories. It serves clinical analysis laboratories, blood donation centers and hospital immunohematology services. The company distributes products in Europe, Asia-Pacific, North America, the Middle East, Latin America and Africa. - Key products include automated immunohematology analyzers, blood screening systems, antigens, leucored and standard blood bags, automated hemostasis analyzers, ELISA kits, coagulation reagents, instrumentation and software. Continue to grow its portfolio of clinical and diagnostic products in autoimmunity and hemostasis areas.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Overview

Provides technology and services for clinics, hospitals and specialized centers for the manufacture of medicines; enteral nutritional fluids such as feeding tubes and nutritional bags; physiological saline solution and medical devices for radiology, urology, hemodynamics and anesthesia. - Key products include isotonic solutions, hypotonic solutions, hypertonic solutions, plasma volume expander solutions, intravenous mixtures, hospital logistics, enteral liquid diets, special complementary diets, and disposable sterile therapeutic medical products. Views product innovation as a major growth driver for the division.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Overview

Includes rendering of manufacturing services to third party companies.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Subscribe for access to business segment analysis Subscribe for access to business segment analysis Get Started



Geographical Segments

Target Markets

Includes Czech Republic, France, Germany, Ireland, Italy, Poland, Portugal, Spain, Sweden, Switzerland.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Performance

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Get started with Company Analytics for access to geographical segment data Get started with Company Analytics for access to geographical segment data Learn More
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer